Literature DB >> 9184201

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

S P Henry1, H Bolte, C Auletta, D J Kornbrust.   

Abstract

The toxicity of ISIS 2302, a phosphorothioate oligonucleotide with antisense activity against human ICAM-1 mRNA, was investigated in cynomolgus monkeys (young adult). The oligonucleotide was administered by slow bolus injection every other day for 28 days (14 doses) at dose levels of 0, 2, 10, and 50 mg/kg/injection. The basic group size consisted of three male and three female monkeys which were sacrificed 2 days after the last dose. An additional 2 monkeys/sex in the vehicle control and 50 mg/kg dose groups remained on study for a 28-day treatment-free period. No treatment-related deaths occurred during this study, however, one monkey in the 10 mg/kg dose group was markedly lethargic after the first dose. Other clinical observations included periocular swelling (> or = 10 mg/kg) on the first day of the study, and bruising in all dose groups throughout the study. Bruising was associated with a dose-dependent prolongation of clotting times, particularly activated partial thromboplastin times (APTT), that was transient in nature. Bruises occurred around site of intravenous dosing or blood collection, and were manifested as subcutaneous hemorrhages upon microscopic evaluation. There were no corresponding alterations in hematology parameters including RBC or platelet counts. Other treatment-related microscopic alterations noted were intracytoplasmic eosinophilic granules and vacuolation in proximal tubular epithelial cells at 10 and 50 mg/kg, with free RBC in renal proximal tubular lumens at 50 mg/kg. Serum chemistry parameters including BUN and creatinine levels were normal in all dose groups and there were no notable alterations in urinalysis parameters. Granules and vacuolations in kidneys were reversed following a 4-week treatment free period. In general, 10 and 50 mg/kg ISIS 2302 produced dose-dependent changes in clotting times and the kidney that were reversible, while 2 mg/kg ISIS 2302 produced no remarkable alterations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184201     DOI: 10.1016/s0300-483x(97)03661-5

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  14 in total

Review 1.  Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.

Authors:  Gregory Benedetto; C Greer Vestal; Christine Richardson
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

2.  Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.

Authors:  Alison J Davis; Karen A Gelmon; Lillian L Siu; Malcolm J Moore; Carolyn D Britten; Nisha Mistry; Henry Klamut; Susan D'Aloisio; Martha MacLean; Nancy Wainman; Debbie Ayers; Patricia Firby; Jeffrey M Besterman; Gregory K Reid; Elizabeth A Eisenhauer
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

3.  Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides.

Authors:  Dali Wang; Qiwei Wang; Yuyan Wang; Peiru Chen; Xueguang Lu; Fei Jia; Yehui Sun; Tingyu Sun; Lei Zhang; Fangyuan Che; Jialu He; Liming Lian; Gemma Morano; Michael Shen; Mengqi Ren; Sijia S Dong; Jean J Zhao; Ke Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-14       Impact factor: 12.779

4.  Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.

Authors:  Raúl Franco; Juan M Rodriguez; Fernanda Elías; Andrés Hernando-Insúa; Juan Fló; Ricardo López; Carlos Nagle; Néstor Lago; Jorge Zorzopulos; David L Horn; Alejandro D Montaner
Journal:  Nucleic Acid Ther       Date:  2014-04-10       Impact factor: 5.486

Review 5.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

6.  Cross-talk between ICAM-1 and granulocyte-macrophage colony-stimulating factor receptor signaling modulates eosinophil survival and activation.

Authors:  Konrad Pazdrak; Travis W Young; Susan Stafford; Barbara Olszewska-Pazdrak; Christof Straub; Vitaliy Starosta; Allan Brasier; Alexander Kurosky
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

7.  Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.

Authors:  Olga A Patutina; Svetlana K Gaponova Miroshnichenko; Aleksandra V Sen'kova; Innokenty A Savin; Daniil V Gladkikh; Ekaterine A Burakova; Alesya A Fokina; Mikhail A Maslov; Elena V Shmendel'; Mattew J A Wood; Valentin V Vlassov; Sidney Altman; Dmitry A Stetsenko; Marina A Zenkova
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-07       Impact factor: 12.779

Review 8.  MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers.

Authors:  Jana Merhautova; Regina Demlova; Ondrej Slaby
Journal:  Front Pharmacol       Date:  2016-09-27       Impact factor: 5.810

9.  In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization.

Authors:  Piotr J Kamola; Jeremy D A Kitson; Gemma Turner; Klio Maratou; Sofie Eriksson; Aliza Panjwani; Linda C Warnock; Gaelle A Douillard Guilloux; Kitty Moores; Emma L Koppe; William E Wixted; Paul A Wilson; Nigel J Gooderham; Timothy W Gant; Kenneth L Clark; Stephen A Hughes; Mark R Edbrooke; Joel D Parry
Journal:  Nucleic Acids Res       Date:  2015-09-03       Impact factor: 16.971

10.  Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia.

Authors:  Sabine Sewing; Adrian B Roth; Michael Winter; Andreas Dieckmann; Cristina Bertinetti-Lapatki; Yann Tessier; Claudia McGinnis; Sylwia Huber; Erich Koller; Corinne Ploix; John C Reed; Thomas Singer; Andreas Rothfuss
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.